## Key Features of the Partnership
Supercharging Medicine Discovery
Eli Lilly is constructing an AI supercomputer, dubbed an "AI factory," which will manage the entire AI lifecycle through data ingestion, training, fine-tuning, and high-volume inference. This infrastructure is designed to support rapid learning and iteration in drug discovery efforts.
Supercomputer Specifications
The supercomputer is an NVIDIA DGX SuperPOD with DGX B300 systems, powered by more than 1,000 B300 GPUs. This setup allows for high-speed communication across GPUs, storage, and related systems, enabling efficient data processing and AI model training.
Applications and Benefits
- **Drug Discovery**: Scientists will be able to train AI models on millions of experiments to identify, optimize, and validate new molecules. This approach will dramatically expand the scope and sophistication of drug discovery efforts.
- **Manufacturing and Medical Imaging**: The supercomputer can improve manufacturing processes by utilizing digital twins and NVIDIA's robotic technologies to enhance production efficiency and reduce downtime. Additionally, advanced medical imaging capabilities will provide clearer insights into disease progression, enabling the development of new biomarkers for personalized care.
AI Models and Platforms
A number of proprietary AI models developed using this supercomputer will be available on Lilly's TuneLab platform, a collaborative federated AI/ML drug discovery platform. TuneLab will incorporate select NVIDIA Clara open-source models to expand access to advanced discovery tools across the biopharma ecosystem.
## Impact on Medicine
The partnership is expected to transform the science of medicine by shifting from trial-and-error discovery to more intentional design of medicines. This collaboration represents a significant step in the AI industrial revolution, particularly in medicine, where AI is becoming a crucial tool for scientific advancement.
Eli Lilly's commitment to innovation and its deep scientific heritage position the company as a leader in this new era of medical discovery. As Kimberly Powell, Vice President of Healthcare at NVIDIA, noted, "Modern AI factories are becoming the new instrument of science — enabling the shift from trial-and-error discovery to a more intentional design of medicines."
The partnership illustrates how AI technology, such as systems developed by NVIDIA, can be pivotal in accelerating drug development and improving patient outcomes. To learn more about NVIDIA's AI solutions, visit the [NVIDIA](https://www.nvidia.com/en-us/) website.
